Article Text

Download PDFPDF
Long-Term Survival After Surgery and Radiotherapy for Recurrent or Persistent Ovarian and Tubal Cancer
  1. Robert Rome, FRCS, (Ed), FRCOG, FRANZCOG, CGO*,
  2. Joanna Dipnall, PhD, B.Ec (Hons) and
  3. Sam Leung, FRANZCR*,
  1. *Epworth HealthCare, Richmond;
  2. School of Medicine, Deakin University, Geelong; and
  3. Radiation Oncology Victoria, Frankston, Victoria, Australia.
  1. Address correspondence and reprint requests to Robert Rome, FRCS(Ed), FRCOG, FRANZCOG, Suite 115, 320 Victoria Parade, East Melbourne, 3002 Victoria, Australia. E-mail:


Objective This study examines the factors associated with long-term disease-specific survival (DSS) and complications after radiotherapy (RT) for recurrent or persistent ovarian and tubal cancer.

Methods/Materials Between 1980 and 2015, 65 women with ovarian (57), tubal (3), or co-existent ovarian/endometrial carcinoma (5) received RT (>45 Gy) with curative intent for recurrent (45) or persistent cancer (20) found at second-look surgery. Surgery to debulk (± restage) was integrated into the management of all but 7 cases.

Results Twenty-two women had no evidence of disease at last contact after a median of 15.6 years (range = 1.0–35.8 years). Of the 53 patients treated more than 10 years ago, 18 (34%) are in this long-term no evidence of disease group. Univariate analysis showed that the following factors were significantly associated with longer DSS (P < 0.05): initial stage I, II (vs III, IV); endometrioid histology (vs serous and other); no or 1 previous chemotherapy (vs ≥2); no macroscopic tumor before RT (vs macroscopic); localized tumor encompassed by a limited-volume RT field (vs more widespread tumor), and chemotherapy and RT (vs RT only). Multivariate analysis showed that endometrioid (vs other histology HR = 4.37, P = 0.017) and localized tumor (vs more widespread tumor, HR = 2.43, P = 0.017) were significantly associated with longer DSS.

After RT to the pelvis and/or abdomen, 13 (21.7%) of 60 patients developed G3 or 4 bowel complications requiring surgery. In 10, these occurred in the presence of tumor, RT changes, and adhesions, and in 3, there was no sign of cancer. Six patients (9.2%) developed a subsequent malignancy.

Conclusions We conclude that there is a role for the use of RT in selected cases of localized recurrent or persistent ovarian cancer and may confer long-term survival. Surgery is useful to debulk and define the extent of tumor to be irradiated but may confer an increased risk of severe bowel complications.

  • Recurrent ovarian cancer
  • Recurrent tubal cancer
  • Radiotherapy
  • Long term survival
  • Secondary debulking

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The study was supported by the Epworth Foundation.

  • The authors declare no conflicts of interest.